Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to assess the efficacy of induction treatment with
buprenorphine/naloxone (BNX) sublingual tablet s compared with induction treatment with
buprenorphine only. The hypothesis is that starting directly on OX219 works equally well
(e.g. not significantly worse) as starting on buprenorphine only and switching to OX219 on
Day 3.
Phase:
Phase 3
Details
Lead Sponsor:
Orexo AB
Collaborator:
Worldwide Clinical Trials
Treatments:
Analgesics, Opioid Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone